Mostrar el registro sencillo del ítem

dc.contributor.authorRubio, Francisco Javier
dc.contributor.authorRedondo Sánchez, Daniel
dc.contributor.authorSánchez Pérez, María José 
dc.contributor.authorLuque Fernández, Miguel Ángel
dc.date.accessioned2022-04-25T12:36:04Z
dc.date.available2022-04-25T12:36:04Z
dc.date.issued2022-04-03
dc.identifier.citationRubio, F.J... [et al.]. Bayesian variable selection and survival modeling: assessing the Most important comorbidities that impact lung and colorectal cancer survival in Spain. BMC Med Res Methodol 22, 95 (2022). [https://doi.org/10.1186/s12874-022-01582-0]es_ES
dc.identifier.urihttp://hdl.handle.net/10481/74541
dc.descriptionMiguel Angel Luque-Fernandez is supported by a Miguel Servet I Investigator award (Grant CP17/00206) and a project grant EU-FEDER-FIS PI-18/01593 from the Instituto de Salud Carlos III, Madrid, Spain. Danilo Alvares is supported by the National Fund for Scientific and Technological Development (FONDECYT, Chile) grant number 11190018.es_ES
dc.description.abstractCancer survival represents one of the main indicators of interest in cancer epidemiology. However, the survival of cancer patients can be affected by several factors, such as comorbidities, that may interact with the cancer biology. Moreover, it is interesting to understand how different cancer sites and tumour stages are affected by different comorbidities. Identifying the comorbidities that affect cancer survival is thus of interest as it can be used to identify factors driving the survival of cancer patients. This information can also be used to identify vulnerable groups of patients with comorbidities that may lead to worst prognosis of cancer. We address these questions and propose a principled selection and evaluation of the effect of comorbidities on the overall survival of cancer patients. In the first step, we apply a Bayesian variable selection method that can be used to identify the comorbidities that predict overall survival. In the second step, we build a general Bayesian survival model that accounts for time-varying effects. In the third step, we derive several posterior predictive measures to quantify the effect of individual comorbidities on the population overall survival. We present applications to data on lung and colorectal cancers from two Spanish population-based cancer registries. The proposed methodology is implemented with a combination of the R-packages mombf and rstan. We provide the code for reproducibility at https://github.com/migariane/ BayesVarImpComorbiCancer.es_ES
dc.description.sponsorshipMiguel Servet I Investigator award CP17/00206 EU-FEDER-FIS PI-18/01593es_ES
dc.description.sponsorshipInstituto de Salud Carlos IIIes_ES
dc.description.sponsorshipComision Nacional de Investigacion Cientifica y Tecnologica (CONICYT) CONICYT FONDECYT 11190018es_ES
dc.language.isoenges_ES
dc.publisherBMCes_ES
dc.rightsAtribución 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subjectBayesian variable selectiones_ES
dc.subjectCancer survivales_ES
dc.subjectComorbiditieses_ES
dc.subjectConditional effectses_ES
dc.subjectMarginal effectses_ES
dc.titleBayesian variable selection and survival modeling: assessing the Most important comorbidities that impact lung and colorectal cancer survival in Spaines_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.doi10.1186/s12874-022-01582-0
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones_ES


Ficheros en el ítem

[PDF]

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 3.0 España
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución 3.0 España